Circulating chemerin decreases in response to a combined strength and endurance training

Endocrine

Volumn 45, Issue 3, 2014, Pages 382-391

  Stefanov, Tsvetan ^a   Blüher, Matthias ^b   Vekova, Anna ^a   Bonova, Iveta ^a   Tzvetkov, Stanislav ^a   Kurktschiev, Dimo ^c   Temelkova Kurktschiev, Theodora ^c  

^a National Sports Academy V Levski   (Bulgaria)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Robert Koch German Medical Center   (Bulgaria)

Author keywords

Adipokines; Cardiovascular disease; Chemerin; Combined exercise; Metabolic disease; Obesity

Indexed keywords

C REACTIVE PROTEIN; CHEMERIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHEMERIN, HUMAN; CHEMOKINE;

ADULT; AEROBIC CAPACITY; AGE; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ENDURANCE TRAINING; FAT FREE MASS; FAT MASS; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEUKOCYTE COUNT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESISTANCE TRAINING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ANTHROPOMETRY; BLOOD; CARDIOVASCULAR DISEASES; ENDURANCE; KINESIOTHERAPY; MIDDLE AGED; OVERWEIGHT; PHYSIOLOGY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTHROPOMETRY; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHEMOKINES; CROSS-SECTIONAL STUDIES; EXERCISE THERAPY; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PHYSICAL ENDURANCE; RESISTANCE TRAINING; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897073251     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0003-2     Document Type: Article

References (48)

1. T. Temelkova-Kurktschiev, T. Stefanov, Lifestyle and genetics in obesity and type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 120(1), 1-6 (2012)
2. P. Hossain, B. Kawar, M. El Nahas, Obesity and diabetes in the developing world-a growing challenge. N. Engl. J. Med. 356(3), 213-215 (2007)
3. H.E. Lebovitz, M.A. Banerji, Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 28(9), 2322-2325 (2005)
4. E.E. Kershaw, J.S. Flier, Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548-2556 (2004)
5. M. Bluher, Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117(6), 241-250 (2009)
6. G.R. Hajer, T.W. van Haeften, F.L. Visseren, Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29(24), 2959-2971 (2008)
7. K. Bozaoglu, K. Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, K. Walder, D. Segal, Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148(10), 4687-4694 (2007)
8. K.B. Goralski, T.C. McCarthy, E.A. Hanniman, B.A. Zabel, E.C. Butcher, S.D. Parlee, S. Muruganandan, C.J. Sinal, Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 282(38), 28175-28188 (2007)
9. M. Takahashi, Y. Takahashi, K. Takahashi, F.N. Zolotaryov, K.S. Hong, R. Kitazawa, K. Iida, Y. Okimura, H. Kaji, S. Kitazawa, M. Kasuga, K. Chihara, Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 582(5), 573-578 (2008)
10. H. Sell, J. Laurencikiene, A. Taube, K. Eckardt, A. Cramer, A. Horrighs, P. Arner, J. Eckel, Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 58(12), 2731-2740 (2009)
11. M.C. Ernst, M. Issa, K.B. Goralski, C.J. Sinal, Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 151(5), 1998-2007 (2010)
12. M. Becker, K. Rabe, C. Lebherz, J. Zugwurst, B. Goke, K.G. Parhofer, M. Lehrke, U.C. Broedl, Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 59(11), 2898-2903 (2010)
13. J. Weigert, M. Neumeier, J. Wanninger, M. Filarsky, S. Bauer, R. Wiest, S. Farkas, M.N. Scherer, A. Schaffler, C. Aslanidis, J. Scholmerich, C. Buechler, Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. (Oxf) 72(3), 342-348 (2010)
14. K. Bozaoglu, D. Segal, K.A. Shields, N. Cummings, J.E. Curran, A.G. Comuzzie, M.C. Mahaney, D.L. Rainwater, J.L. Vande-Berg, J.W. MacCluer, G. Collier, J. Blangero, K. Walder, J.B. Jowett, Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J. Clin. Endocrinol. Metab. 94(8), 3085-3088 (2009)
15. R. Chakaroun, M. Raschpichler, N. Kloting, A. Oberbach, G. Flehmig, M. Kern, M.R. Schon, E. Shang, T. Lohmann, M. Dressler, M. Fasshauer, M. Stumvoll, M. Bluher, Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism (2011). doi:10.1016/j.metabol.2011.10.008
16. T. Sledzinski, J. Korczynska, A. Hallmann, L. Kaska, M. Proczko- Markuszewska, T. Stefaniak, M. Sledzinski, J. Swierczynski, The increase of serum chemerin concentration is mainly associated with the increase of BMI in obese, non-diabetic subjects. J. Endocrinol. Invest. (2012). doi:10.3275/8770
17. A. Tonjes, M. Fasshauer, J. Kratzsch, M. Stumvoll, M. Bluher, Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 5(11), e13911 (2010)
18. M. Yang, G. Yang, J. Dong, Y. Liu, H. Zong, H. Liu, G. Boden, L. Li, Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J. Investig. Med. 58(7), 883-886 (2010)
19. S.H. Chu, M.K. Lee, K.Y. Ahn, J.A. Im, M.S. Park, D.C. Lee, J.Y. Jeon, J.W. Lee, Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 7(4), e34710 (2012)
20. N. Kloting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schon, M. Kern, M. Stumvoll, M. Bluher, Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299(3), E506-E515 (2010)
21. A.A. Roman, S.D. Parlee, C.J. Sinal, Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 42(2), 243-251 (2012)
22. D.M. Ouwens, M. Bekaert, B. Lapauw, Y. Van Nieuwenhove, S. Lehr, S. Hartwig, P. Calders, J.M. Kaufman, H. Sell, J. Eckel, J.B. Ruige, Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch. Physiol. Biochem. 118(3), 135-138 (2012)
23. S.N. Blair, J.N. Morris, Healthy hearts-and the universal benefits of being physically active: physical activity and health. Ann. Epidemiol. 19(4), 253-256 (2009)
24. T. Stefanov, A. Vekova, I. Bonova, S. Tzvetkov, D. Kurktschiev, M. Bluher, T. Temelkova-Kurktschiev, Effects of supervised vs non-supervised combined aerobic and resistance exercise programme on cardiometabolic risk factors. Cent. Eur. J. Public Health 21(1), 239-243 (2013)
25. M. Venojarvi, N. Wasenius, S. Manderoos, O.J. Heinonen, M. Hernelahti, H. Lindholm, J. Surakka, J. Lindstrom, S. Aunola, M. Atalay, J.G. Eriksson, Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann. Med. (2012). doi:10.3109/07853890. 2012.727020
26. B.E. Ainsworth, W.L. Haskell, S.D. Herrmann, N. Meckes, D.R. Bassett Jr., C. Tudor-Locke, J.L. Greer, J. Vezina, M.C. Whitt-Glover, A.S. Leon, Compendium of Physical Activities: a second update of codes and MET values. Med. Sci. Sports Exerc. 43(8), 1575-1581 (2011)
27. V. Noonan, E. Dean, Submaximal exercise testing: clinical application and interpretation. Phys. Ther. 80(8), 782-807 (2000)
28. C. Foster, A.S. Jackson, M.L. Pollock, M.M. Taylor, J. Hare, S.M. Sennett, J.L. Rod, M. Sarwar, D.H. Schmidt, Generalized equations for predicting functional capacity from treadmill performance. Am. Heart J. 107(6), 1229-1234 (1984)
29. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412-419 (1985)
30. P. Zimmet, D. Magliano, Y. Matsuzawa, G. Alberti, J. Shaw, The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 12(6), 295-300 (2005)
31. M. Lehrke, A. Becker, M. Greif, R. Stark, R.P. Laubender, F. von Ziegler, C. Lebherz, J. Tittus, M. Reiser, C. Becker, B. Goke, A.W. Leber, K.G. Parhofer, U.C. Broedl, Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol. 161(2), 339-344 (2009)
32. D. Stejskal, M. Karpisek, Z. Hanulova, M. Svestak, Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 152(2), 217-221 (2008)
33. H.Y. Shin, D.C. Lee, S.H. Chu, J.Y. Jeon, M.K. Lee, J.A. Im, J.W. Lee, Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin. Endocrinol. (Oxf) (2011). doi:10.1111/j.1365-2265.2011. 04217.x
34. B. Dong, W. Ji, Y. Zhang, Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern. Med. 50(10), 1093-1097 (2011)
35. V. Catalan, J. Gomez-Ambrosi, A. Rodriguez, B. Ramirez, F. Rotellar, V. Valenti, C. Silva, M.J. Gil, J. Salvador, G. Fruhbeck, Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg. Obes. Relat. Dis. (2011). doi:10.1016/j.soard.2011.11.001
36. S. Bauer, M. Bala, A. Kopp, K. Eisinger, A. Schmid, S. Schneider, M. Neumeier, C. Buechler, Adipocyte chemerin release is induced by insulin without being translated to higher levels in vivo. Eur. J. Clin. Invest. 42(11), 1213-1220 (2012)
37. B.K. Tan, J. Chen, S. Farhatullah, R. Adya, J. Kaur, D. Heutling, K.C. Lewandowski, J.P. O'Hare, H. Lehnert, H.S. Randeva, Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 58(9), 1971-1977 (2009)
38. M.C. Ernst, C.J. Sinal, Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol. Metab. 21(11), 660-667 (2010)
39. M. Bluher, A. Rudich, N. Kloting, R. Golan, Y. Henkin, E. Rubin, D. Schwarzfuchs, Y. Gepner, M.J. Stampfer, M. Fiedler, J. Thiery, M. Stumvoll, I. Shai, Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 35(2), 342-349 (2012)
40. H. Sell, A. Divoux, C. Poitou, A. Basdevant, J.L. Bouillot, P. Bedossa, J. Tordjman, J. Eckel, K. Clement, Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 95(6), 2892-2896 (2010)
41. C. Ress, A. Tschoner, J. Engl, A. Klaus, H. Tilg, C.F. Ebenbichler, J.R. Patsch, S. Kaser, Effect of bariatric surgery on circulating chemerin levels. Eur. J. Clin. Invest. 40(3), 277-280 (2010)
42. T.A. Lakka, D.E. Laaksonen, H.M. Lakka, N. Mannikko, L.K. Niskanen, R. Rauramaa, J.T. Salonen, Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med. Sci. Sports Exerc. 35(8), 1279-1286 (2003)
43. P.T. Katzmarzyk, T.S. Church, S.N. Blair, Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch. Intern. Med. 164(10), 1092-1097 (2004)
44. D.C. Lee, X. Sui, T.S. Church, I.M. Lee, S.N. Blair, Associations of cardiorespiratory fitness and obesity with risks of impaired fasting glucose and type 2 diabetes in men. Diabetes Care 32(2), 257-262 (2009)
45. D. Stensvold, A.E. Tjonna, E.A. Skaug, S. Aspenes, T. Stolen, U. Wisloff, S.A. Slordahl, Strength training versus aerobic interval training to modify risk factors of metabolic syndrome. J. Appl. Physiol. 108(4), 804-810 (2010)
46. C.A. Libardi, G.V. De Souza, C.R. Cavaglieri, V.A. Madruga, M.P. Chacon-Mikahil, Effect of resistance, endurance, and concurrent training on TNF-alpha, IL-6, and CRP. Med. Sci. Sports Exerc. 44(1), 50-56 (2012)
47. L.A. Bateman, C.A. Slentz, L.H. Willis, A.T. Shields, L.W. Piner, C.W. Bales, J.A. Houmard, W.E. Kraus, Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise-STRRIDE-AT/RT). Am. J. Cardiol. 108(6), 838-844 (2011)
48. C.A. Slentz, L.A. Bateman, L.H. Willis, A.T. Shields, C.J. Tanner, L.W. Piner, V.H. Hawk, M.J. Muehlbauer, G.P. Samsa, R.C. Nelson, K.M. Huffman, C.W. Bales, J.A. Houmard, W.E. Kraus, Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in over-weight adults from STRRIDE AT/RT. Am. J. Physiol. Endocrinol. Metab. 301(5), E1033-E1039 (2011)